Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Revenue increased 11.4 per cent to Rs. 8,545 crore
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
The coating is designed for heat-sealable applications, offering oil and grease resistance on kraft paper and suitable blister coatings for paper and paperboard
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Subscribe To Our Newsletter & Stay Updated
